Recently added
This page was added on 27 June 2024.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Registered for use in adults aged ≥60 years and adults 50–59 years who are at increased risk for RSV disease
Recombinant Respiratory Syncytial Virus (RSV) pre-fusion F protein (RSVPreF3) (AS01E adjuvanted vaccine)
Powder and suspension for injection
Each 0.5mL reconstituted dose (powder) contains:
- 120µg of RSVPreF3 antigen
- trehalose dihydrate
- polysorbate 80
- monobasic potassium phosphate
- dibasic potassium phosphate
These are adjuvanted with AS01E adjuvant system (suspension). The adjuvant includes:
- 25µg Quillaja saponaria saponin (QS-21)
- 25µg 3-O-desacyl-4’-monophosphoryl lipid A (MPL)
- dioleoylphosphatidylcholine
- cholesterol
- sodium chloride
- dibasic sodium phosphate
- monobasic potassium phosphate
For Product Information and Consumer Medicine Information about Arexvy vaccine visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.